“Health Minute” brings original health care and health policy reporting from the KFF Health News newsroom to the airwaves each week. (3/18) Here's today's health policy haiku: ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan ...

The presentations will be available in the Publications ... including Novartis' Zolgensma ® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have ...

The oral presentations feature data from the ongoing CONNECT1-EDO51 clinical trial in Duchenne muscular dystrophy (DMD) and from the ongoing FREEDOM-DM1 clinical trial in myotonic dystrophy type 1 ...

will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44). March 16-18, 2025: 6:00 p.m ...

The presentations will be available in the Publications section ... including Novartis' Zolgensma ® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have ...

today announced that the company will present preclinical data from the PBGENE-DMD program for the treatment of Duchenne muscular dystrophy (DMD) during an oral presentation at the 2025 Muscular ...